SILDENAFIL RESEARCH LIQUID: WHAT IS IT?
04OctOctober 4, 2022
Sildenafil citrate functions as a PDE type 5 inhibitor (PDE5Is), a classification of compounds that extend the physiological effects of nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling in tissues by inhibiting cGMP degradation.
Research suggests that sildenafil was initially investigated for potential applications related to hypertension and angina conditions. Interestingly, unexpected physiological responses observed in research models led to investigations in erectile function mechanisms and, subsequently, pulmonary arterial hypertension research. Sildenafil oral suspension is particularly significant in treating pulmonary arterial hypertension (PAH) in both adults and pediatrics, with specific formulation, dosage recommendations, and storage requirements. Laboratory studies indicate potential interactions between sildenafil citrate and nitrate-containing substances used in hypertension research, suggesting careful consideration when studying these compounds in combination.
PHARMACOLOGY OF SILDENAFIL IN ERECTILE DYSFUNCTION RESEARCH
Within research settings, sildenafil operates by inhibiting an enzyme called cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. For laboratory investigations, sildenafil is available in various research formulations. Sildenafil tablets are commonly used in erectile dysfunction research due to their well-documented formulation and pharmacological mechanism as a phosphodiesterase-5 inhibitor.
cGMP plays a significant role in relaxing smooth muscles in the vasculature supplying blood to the corpus cavernosum, the spongy tissue that becomes engorged during erection in experimental models. When investigating sildenafil, researchers should consider potential interactions with nutritional factors and other compounds, as well as specific laboratory precautions and observed physiological responses.
By inhibiting PDE5, research suggests sildenafil prevents cGMP breakdown, meaning increased availability for smooth muscle relaxation and enhanced blood flow in research models. However, this does not suggest sildenafil directly causes physiological responses without appropriate stimulation.
How Does Sildenafil Function in Research Models?
In laboratory investigations, sildenafil acts as a phosphodiesterase type 5 (PDE5) inhibitor, functioning by blocking the activity of the phosphodiesterase type 5 enzyme. This enzyme normally breaks down cyclic guanosine monophosphate (cGMP), a molecule involved in smooth muscle relaxation in vascular tissues.
Research suggests that when sildenafil is administered in experimental settings, it increases cGMP levels in blood vessels, potentially promoting smooth muscle relaxation and vasodilation. This enhanced blood flow mechanism has been studied in erectile function research by allowing increased circulation to relevant tissues in research models. PDE-5 inhibitors like sildenafil are used to treat erectile dysfunction by enhancing blood flow to relevant tissues.
In pulmonary arterial hypertension (PAH) investigations, research indicates sildenafil may function by relaxing pulmonary blood vessels, potentially reducing pressure in pulmonary arteries and improving circulatory parameters. Laboratory studies suggest this mechanism might influence physiological markers associated with pulmonary function.
Research Investigations
Several laboratory investigations have been conducted to evaluate the properties of sildenafil in various research models.
In a study published in the New England Journal of Medicine, sildenafil demonstrated effectiveness in erectile function research across various experimental conditions, including models simulating diabetes, hypertension, and cardiovascular variations.
Another investigation published in the Journal of the American College of Cardiology found that sildenafil appeared to improve exercise capacity parameters and reduce certain physiological markers in pulmonary arterial hypertension research models. Sildenafil is also used to treat pulmonary arterial hypertension, showing effectiveness in improving exercise capacity and reducing physiological markers in PAH research models.
Research published in the European Respiratory Journal indicated sildenafil improved pulmonary function metrics and reduced specific markers in chronic thromboembolic pulmonary hypertension investigation models.
WHAT IS SILDENAFIL USED FOR?
Sildenafil is a versatile medication primarily used to treat two significant conditions: erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). Erectile dysfunction is characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. This condition can significantly impact quality of life and emotional well-being. On the other hand, pulmonary arterial hypertension is a type of high blood pressure that specifically affects the arteries in the lungs. This condition makes it challenging for the heart to pump blood through these arteries, leading to symptoms such as shortness of breath, dizziness, and fatigue. By addressing these conditions, sildenafil helps improve overall cardiovascular health and quality of life.
IMPORTANT SAFETY INFORMATION
Sildenafil is a prescription medication that should be taken only under the guidance of a healthcare provider. Adhering to the recommended dosage and administration instructions is crucial to minimize the risk of adverse reactions. One of the significant safety concerns with sildenafil is its potential to cause a sudden drop in blood pressure, which can be life-threatening. Therefore, it is essential to inform your healthcare provider about any existing medical conditions, such as heart problems, low blood pressure, or stomach ulcers. This information helps ensure that sildenafil is safe and appropriate for your specific health needs.
RESEARCH APPLICATIONS
Sildenafil has been investigated for the following research applications:
Erectile function mechanisms in research models
Pulmonary arterial hypertension (PAH) in laboratory investigations
Chronic thromboembolic pulmonary hypertension (CTEPH) in experimental settings
Sildenafil for oral suspension in treating pulmonary arterial hypertension and erectile dysfunction in research models
RESEARCH QUANTITIES AND ADMINISTRATION PROTOCOLS
For erectile function research, investigations typically utilize 50 mg of sildenafil administered approximately 1 hour before monitoring physiological responses. The quantity may be adjusted based on research parameters and observed responses.
In research settings, sildenafil for oral suspension is also used, with its formulation designed for effective administration and ease of use. This oral suspension is particularly noted for its palatable grape flavor, making it easier for patients, especially children, to take the medication.
For PAH investigations, research protocols often employ 20 mg administered three times daily, with approximate 6-8 hour intervals between administrations.
Research Formulations and Administration Protocols: Sildenafil for Oral Suspension
For laboratory investigations, sildenafil is available in the following formulations:
Liquid suspension: 10 mg/mL, grape flavored, 112 mL container
Solid formulations: 25 mg, 50 mg, and 100 mg
In research settings, sildenafil should be administered according to established laboratory protocols. Following recommended quantities and administration guidelines is important to ensure valid and reproducible research outcomes.
Research data indicates that sildenafil should not be investigated alongside certain other compounds, such as nitrates, and special considerations should be implemented when studying models with certain physiological conditions, including altered blood pressure parameters and gastrointestinal presentations.
It is crucial to avoid using too much sildenafil, as this can lead to severe side effects, particularly related to heart problems and interactions with other medications. If an overdose occurs, immediate medical help should be sought, and healthcare providers should be informed about the sildenafil usage.
OBSERVED PHYSIOLOGICAL RESPONSES IN RESEARCH MODELS: BLOOD PRESSURE
Common responses observed in research models include:
Digestive discomfort of mild or moderate intensity
Muscular discomfort occurring at notable frequency
Visual perception alterations
Cephalic discomfort and vascular dilation
Reduced blood pressure parameters and equilibrium disruption
Nasal tissue inflammation
Prolonged vascular engorgement
Decreased blood pressure
Research suggests that excessive administration of sildenafil may lead to significant physiological disruptions, including substantial responses and interactions with other compounds. Laboratory safety protocols recommend immediate intervention in cases of quantity miscalculations and documentation of sildenafil administration, particularly in emergency research scenarios.
ADVERSE REACTIONS AND SIDE EFFECTS
Common side effects of sildenafil include headaches, flushing, indigestion, nasal congestion, dizziness, and visual disturbances. These side effects are generally mild and temporary. However, in rare cases, sildenafil can cause more severe side effects, such as sudden vision loss, hearing impairment, or prolonged erections lasting more than four hours, a condition known as priapism. If you experience any of these severe symptoms, it is crucial to seek medical attention immediately to prevent long-term damage.
DRUG INTERACTIONS
Sildenafil can interact with various other medications, which can increase the risk of adverse reactions. Notably, taking sildenafil with nitrates, often prescribed for chest pain, can lead to a dangerous drop in blood pressure. Additionally, sildenafil can interact with blood thinners, certain antidepressants, and other medications. It is essential to inform your healthcare provider about all the medications you are currently taking, including prescription and over-the-counter drugs, vitamins, and herbal supplements. This comprehensive disclosure helps your healthcare provider manage potential drug interactions and ensure the safe use of sildenafil.
By following these guidelines and working closely with your healthcare provider, you can safely incorporate sildenafil into your treatment plan, whether for erectile dysfunction or pulmonary arterial hypertension.
[WHERE TO OBTAIN SILDENAFIL CITRATE FOR LABORATORY RESEARCH](https://lotilabs.com/research-liquids/sildenafil.html)
When seeking research compounds online, it is essential to source materials from established laboratories to ensure research integrity.
Loti Labs provides research materials at competitive prices with accompanying quality analysis documentation. Our research support team offers comprehensive assistance and a satisfaction guarantee for sildenafil research materials. Additionally, sildenafil oral suspension is available for research purposes from established laboratories, ensuring you have access to high-quality materials for your studies.
Visit our website or contact our research support team to obtain sildenafil for your laboratory investigations.
References:
Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996 Jun;8(2):47-52. [Article]
Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM: ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999 Jan;33(1):273-82. [Article]
Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005 Nov 8;112(19):2980-5. [Article]
Unegbu C, Noje C, Coulson JD, Segal JB, Romer L: Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors. Pediatrics. 2017 Mar;139(3). pii: peds.2016-1450. doi: 10.1542/peds.2016-1450. [Article]
Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T, Luo Y, Huang J: Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017 Oct;49(10):1731-1740. doi: 10.1007/s11255-017-1644-5. Epub 2017 Jul 24. [Article]
Goldstein I, Burnett AL, Rosen RC, Park PW, Stecher VJ: The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. Sex Med Rev. 2019 Jan;7(1):115-128. doi: 10.1016/j.sxmr.2018.06.005. Epub 2018 Oct 6. [Article]
